Ethicon Endo-Surgery first quarter product launches include Optiview optical obturator.
This article was originally published in The Gray Sheet
Executive SummaryETHICON ENDO-SURGERY ENDOPATH OPTIVIEW OPTICAL SURGICAL OBTURATOR is among several endoscopic surgery products being introduced by the firm in the first quarter. Launching in February, Optiview is designed to improve "surgeon visualization during insertion," the company says.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.